一种作为胶质母细胞瘤生物标志物的脑脊液微小RNA特征
A cerebrospinal fluid microRNA signature as biomarker for glioblastoma.
作者信息
Akers Johnny C, Hua Wei, Li Hongying, Ramakrishnan Valya, Yang Zixiao, Quan Kai, Zhu Wei, Li Jie, Figueroa Javier, Hirshman Brian R, Miller Brittney, Piccioni David, Ringel Florian, Komotar Ricardo, Messer Karen, Galasko Douglas R, Hochberg Fred, Mao Ying, Carter Bob S, Chen Clark C
机构信息
Center for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
出版信息
Oncotarget. 2017 Jun 1;8(40):68769-68779. doi: 10.18632/oncotarget.18332. eCollection 2017 Sep 15.
PURPOSE
To develop a cerebrospinal fluid (CSF) miRNA diagnostic biomarker for glioblastoma.
EXPERIMENTAL DESIGN
Glioblastoma tissue and matched CSF from the same patient (obtained prior to tumor manipulation) were profiled by TaqMan OpenArray Human MicroRNA Panel. CSF miRNA profiles from glioblastoma patients and controls were created from three discovery cohorts and confirmed in two validation cohorts.
RESULTS
miRNA profiles from clinical CSF correlated with those found in glioblastoma tissues. Comparison of CSF miRNA profiles between glioblastoma patients and non-brain tumor patients yielded a tumor "signature" consisting of nine miRNAs. The "signature" correlated with glioblastoma tumor volume (=0.008). When prospectively applied to cisternal CSF, the sensitivity and specificity of the 'signature' for glioblastoma detection were 67% and 80%, respectively. For lumbar CSF, the sensitivity and specificity of the signature were 28% and 95%, respectively. Comparable results were obtained from analyses of CSF extracellular vesicles (EVs) and crude CSF.
CONCLUSION
We report a CSF miRNA signature as a "liquid biopsy" diagnostic platform for glioblastoma.
目的
开发一种用于胶质母细胞瘤的脑脊液（CSF）微小RNA（miRNA）诊断生物标志物。
实验设计
使用TaqMan OpenArray人类微小RNA检测板对来自同一患者（在肿瘤处理前获取）的胶质母细胞瘤组织和匹配的脑脊液进行分析。胶质母细胞瘤患者和对照的脑脊液miRNA谱来自三个发现队列，并在两个验证队列中得到证实。
结果
临床脑脊液的miRNA谱与胶质母细胞瘤组织中的miRNA谱相关。胶质母细胞瘤患者与非脑肿瘤患者脑脊液miRNA谱的比较产生了一个由9种miRNA组成的肿瘤“特征”。该“特征”与胶质母细胞瘤肿瘤体积相关（=0.008）。当前瞻性应用于脑池脑脊液时，该“特征”检测胶质母细胞瘤的敏感性和特异性分别为67%和80%。对于腰段脑脊液，该特征的敏感性和特异性分别为28%和95%。对脑脊液细胞外囊泡（EVs）和粗制脑脊液的分析也得到了类似结果。
结论
我们报告了一种脑脊液miRNA特征作为胶质母细胞瘤的“液体活检”诊断平台。
Zotero 插件